Categories Analysis, Technology

DocuSign (DOCU) is expanding beyond e-signature. What future holds

The management sees 6% and 9% year-over-year increases in fourth-quarter and full-year revenues, respectively

During the COVID era, DocuSign, Inc. (NASDAQ: DOCU) reaffirmed its position as the market leader in e-signature services as demand increased sharply due to the movement restrictions, but growth slowed after the peak of the pandemic. Currently, the company is expanding beyond its main business to areas like intelligent agreement management.

The tech firm’s stock slipped soon after last week’s earnings announcement but quickly regained momentum and crossed the $50 mark. While the stock is trading almost in line with the 12-month average, it continues to languish way below the 2021 peak. From an investment perspective, the valuation is cheap. It would be a good idea to add DOCU to the watchlist and keep track of the management’s growth initiatives.

The Market

Being a first-mover in the e-signature space, DocuSign enjoys a clear edge over competitors. Considering the continued strong adoption of e-agreements, the company sees significant opportunities with both existing and new clients. The international business, which is an important part of its addressable market, is expanding faster than the domestic segment.

Over the years, the DocuSign Agreement Cloud platform has expanded steadily and now features multiple applications for managing different stages of the contract lifecycle. However, it is yet to contribute meaningfully to the top line, and the company continues to depend on the e-signature business for revenue. Diversification of the business across all major industries enables the company to effectively deal with competition and lessen the impact of economic slowdown and softness in enterprise spending. However, macro uncertainties will likely remain a concern for the leadership in the near future.

Key Numbers

In the past two years, DocuSign has beaten quarterly earnings estimates consistently. In the October quarter, adjusted net income surged 39% to $0.79 per share. That reflects a 9% growth in the core subscription business. Total revenue rose to about $700 billion and topped expectations. At $692 million, Q3 billings were up 5%. Free cash flow reached a record high of $240 billion, representing a margin of 34%. Adjusted operating margin rose to an all-time high of 27%.

From DocuSign’s Q3 2024 earnings call:

“As we look ahead, we envision serving similar customer needs not addressed by CLM via a broader agreement management platform designed for all of our customers in all segments. We are previewing with select customers now, and we’ll have much more to share on our product roadmap and strategic vision at our Momentum user conference in April 2024. Across both our eSignature core and future agreement management products, we believe our investment will lead to even further differentiation in a competitive market.”

Outlook

Anticipating demand conditions to remain strong in the final months of the fiscal year, the company forecasts Q4 revenues in the range of $696 million to $700 million, and total billings between $758 million and $768 million. Full-year revenue is expected to be around $2.75 billion, and billings above $2.83 billion.  

DocuSign’s stock gained an impressive 6% on Monday afternoon, extending the post-earnings upswing. With only a few weeks left before year-end, DOCU has grown about 27% so far in 2023.

Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.

Most Popular

CVX Earnings: Chevron reports lower revenue and profit for Q1 2024

Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or

ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up

Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net

CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results

Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top